ClinicalTrials.gg
CompletedNCT01987505Updated Dec 26, 2018Results posted

MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

A Phase 3 interventional study of Rituximab in Lymphoma, Non Hodgkin, sponsored by Hoffmann-La Roche. Completed at 39 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
30th of 171
140 · median 38
Started
2013
with 7 others
Phase 3
29 of 178
none open now
Registered
139th of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 30th largest by enrollment of the 171 interventional ones that give a count, is one of 8 that started in 2013, is one of 29 in phase 3, and was the 139th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) who have already received at least one full dose of rituximab IV. Participants with FL will be given 1400 mg rituximab SC during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). 1400 mg SC of rituximab will be given to participants with DLBCL once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.

03

Conditions studied

  • Lymphoma, Non Hodgkin
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and ≤ 80 years at time of enrolment.
  • ≥ 6 months.
  • (ECOG) performance status ≤ 3.
  • Fertile men or women of must use effective until at least 12 months after the last dose; women must not be pregnant.
  • confirmed CD20+ diffuse large B-cell lymphoma (DLBCL) or CD20+ follicular Non-Hodgkin Lymphoma (FL) grade 1, 2 or 3a according to the World Health Organisation Classification system.

Induction only:

  • Participants with Follicular Lymphoma should meet Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria to initiate treatment.
  • At least tumor >/= 1.5 cm as measured by computed tomography (CT) scan.

FL treatment-related criteria

  • Currently being treated with rituximab IV during therapy and has received at least one full dose of rituximab IV.

Exclusion criteria

Exclusion Criteria:

  • Transformed lymphoma.
  • Primary central nervous system lymphoma, primary effusion lymphoma, primary mediastinal DLBCL, DLBCL of the testis, primary cutaneous DLBCL or histologic evidence of transformation to a Burkitt lymphoma.
  • History of other cancer, including one that has been treated but not with curative intent, unless the cancer has been in remission without treatment for >/= 5 years prior to dosing. Note: Participants with a history of cured skin cancer or in situ carcinoma of the cervix are eligible for the study.
  • Ongoing use > 30 mg/day of prednisone or equivalent. Note: Participants receiving corticosteroid treatment with \</= 30 mg/day of prednisone or equivalent must be on a stable regimen for at least 4 weeks prior to start of dosing.
  • Inadequate renal, hematologic, or hepatic function.
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.
  • For participants with DLBCL: to any of the individual components of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone), including prior anthracycline treatment.
  • For participants with FL: contraindication to standard chemotherapy.
  • Other serious underlying medical conditions.
  • Recent major surgery (within 4 weeks prior to dosing), other than for diagnosis.
  • Active and/or severe infections (excluding nail fungal infections) or any infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to dosing.
  • Active virus (HBV) or virus (HCV) infection. Note: Participants testing positive for Hepatitis B or C virus antibodies but with an undetectable viral load may be included.
  • History of (HIV) positive status.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Subcutaneous Rituximab

    Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.

    Drug: Rituximab

Interventions

  • 1400 mg will be injected subcutaneously (SC).

    Also known as: MabThera, Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Administration-Associated Reactions (AARs)

    AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab SC administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

    Time frame: From start of treatment to end of treatment (up to 32 months)

Secondary outcomes

  1. Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.

    Time frame: From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months)

  2. Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)

    Grading of IIRRs was completed according to the CTCAE, version 4.0.

    Time frame: From start of treatment to end of treatment (up to 32 months)

  3. Percentage of Participants With At Least One Serious Adverse Event (SAE)

    SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

    Time frame: From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months)

  4. Event-Free Survival (EFS)

    EFS was defined as the time from first dose of rituximab IV to first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.

    Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)

  5. Progression-Free Survival (PFS)

    PFS was defined as the time from first dose of rituximab IV to the first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or death from any cause. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.

    Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)

  6. Overall Survival (OS)

    OS was defined as the time from first dose of rituximab IV to death from any cause.

    Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)

  7. Disease-Free Survival (DFS)

    DFS was assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow. Reported here is the truncated mean estimate based on Kaplan-Meier analysis.

    Time frame: From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)

  8. Treatment Response Rate

    Treatment response rate was classified according to the International Working Group (IWG) response criteria: CR/Cru, partial response (PR), stable disease (SD) and PD. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow; PR: \>/= 50% decrease lymph nodes and nodal mass size; decrease in liver/spleen size, no new sites; SD: less than a PR, but is not PD; PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.

    Time frame: 4-6 weeks after the last dose of Induction (Up to approximately 8 months)

07

Results

Posted Jul 5, 2018

Participant flow

Participant flow — Overall Study
MilestoneSubcutaneous Rituximab
Started140
Completed106
Not completed34
Withdrew: Other9
Withdrew: Withdrawal by subject2
Withdrew: Other reason2
Withdrew: Lost to follow-up15
Withdrew: Investigator decision2
Withdrew: Death4

Outcome measures

PrimaryPercentage of Participants With Administration-Associated Reactions (AARs)

AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab SC administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

Time frame:
From start of treatment to end of treatment (up to 32 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Administration-Associated Reactions (AARs)
percentage of participantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
At Least One AAR34.552.348.6
At Least One AAR Grade ≥ 302.72.1
At Least One Serious AARs01.81.4
Generalised or Remote from the Injection Site AARs57.911.115.1
Localised at the injection site AARs42.188.984.9
SecondaryPercentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.

Time frame:
From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)
percentage of participantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)48.336.038.6
SecondaryPercentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)

Grading of IIRRs was completed according to the CTCAE, version 4.0.

Time frame:
From start of treatment to end of treatment (up to 32 months)
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)
percentage of participantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)0.02.72.1
SecondaryPercentage of Participants With At Least One Serious Adverse Event (SAE)

SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

Time frame:
From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Serious Adverse Event (SAE)
percentage of participantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Percentage of Participants With At Least One Serious Adverse Event (SAE)37.927.930.0
SecondaryEvent-Free Survival (EFS)

EFS was defined as the time from first dose of rituximab IV to first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.

Time frame:
From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Reported as:
Mean · months
Event-Free Survival (EFS)
monthsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Event-Free Survival (EFS)25.79 (20.800 to 30.776)54.39 (51.416 to 57.362)52.314 (49.162 to 55.466)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from first dose of rituximab IV to the first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or death from any cause. PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.

Time frame:
From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Reported as:
Mean · months
Progression-Free Survival (PFS)
monthsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Progression-Free Survival (PFS)27.952 (23.443 to 32.460)54.389 (51.416 to 57.362)53.118 (50.108 to 56.127)
SecondaryOverall Survival (OS)

OS was defined as the time from first dose of rituximab IV to death from any cause.

Time frame:
From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Reported as:
Mean · months
Overall Survival (OS)
monthsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Overall Survival (OS)37.42 (33.354 to 41.485)60.61 (59.692 to 61.535)59.516 (57.999 to 61.033)
SecondaryDisease-Free Survival (DFS)

DFS was assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow. Reported here is the truncated mean estimate based on Kaplan-Meier analysis.

Time frame:
From time of first dose of rituximab IV before study enrollment up to end of study (up to approximately 62 months)
Reported as:
Mean · months
Disease-Free Survival (DFS)
monthsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Disease-Free Survival (DFS)26.062 (23.510 to 28.613)NA (NA to NA)33.044 (31.489 to 34.600)
SecondaryTreatment Response Rate

Treatment response rate was classified according to the International Working Group (IWG) response criteria: CR/Cru, partial response (PR), stable disease (SD) and PD. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \> 75% decrease in residual lymph node mass, indeterminate bone marrow; PR: \>/= 50% decrease lymph nodes and nodal mass size; decrease in liver/spleen size, no new sites; SD: less than a PR, but is not PD; PD: \>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.

Time frame:
4-6 weeks after the last dose of Induction (Up to approximately 8 months)
Reported as:
Number · percentage of participants
Treatment Response Rate
percentage of participantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous Rituximab
Complete Response (CR)62.166.764.3
Complete Response Unconfirmed (CRU)3.47.45.4
Partial Response (PR)3.411.17.1
Stable Disease (SD)0.03.71.8
Progressive disease (PD)17.27.412.5
Unable to Assess (UA)6.90.03.6
Not Evaluable6.93.75.4

Adverse events

Collected over From start of recruitment (10 months period) up to end of treatment at 32 months (total period up to 42 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subcutaneous Rituximab4/140 (2.9%)42/140 (30%)117/140 (83.6%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventSubcutaneous Rituximab
Febrile neutropeniaBlood and lymphatic system disorders12/140
NeutropeniaBlood and lymphatic system disorders10/140
PneumoniaInfections and infestations4/140
Respiratory tract infectionInfections and infestations4/140
GastroenteritisInfections and infestations3/140
Abdominal painGastrointestinal disorders2/140
Pneumonia pneumococcalInfections and infestations2/140
UrosepsisInfections and infestations2/140
AgranulocytosisBlood and lymphatic system disorders1/140
Atrial fibrillationCardiac disorders1/140
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSubcutaneous Rituximab
ErythemaSkin and subcutaneous tissue disorders36/140
AstheniaGeneral disorders31/140
NeutropeniaBlood and lymphatic system disorders24/140
Respiratory tract infectionInfections and infestations23/140
DiarrhoeaGastrointestinal disorders22/140
Viral upper respiratory tract infectionInfections and infestations21/140
Back painMusculoskeletal and connective tissue disorders15/140
PyrexiaGeneral disorders14/140
ParaesthesiaNervous system disorders14/140
CoughRespiratory, thoracic and mediastinal disorders14/140

Baseline characteristics

Intent-to-Treat (ITT) population included all enrolled participants. All analyses described have been performed by type of lymphoma (DLBCL/ FL) and overall.

Age, Continuous
Age, Continuous(years)Diffuse Large B-Cell LymphomaFollicular LymphomaTotal
Mean62.5 ± 12.059.6 ± 12.560.2 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Diffuse Large B-Cell LymphomaFollicular LymphomaTotal
Female175875
Male125365
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Diffuse Large B-Cell LymphomaFollicular LymphomaTotal
Black011
Caucasian29110139
08

Study locations

39 sites
  • Hospital De Txagorritxu; Servicio de Hematologia
    Vitoria, Alava 01009, Spain
  • Hospital General de Elda; Servicio de Hematologia
    Elda, Alicante 03600, Spain
  • Hospital de Granollers, Servicio de Hematología
    Granollers, Barcelona 08400, Spain
  • Hospital Mutua de Terrassa; Servicio de Hematologia
    Terrassa, Barcelona 08221, Spain
  • Hospital Son Llatzer; Servicio de Hematologia
    Palma de Mallorca, Islas Baleares 07198, Spain
  • Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia
    La Coruna, LA Coruña 15006, Spain
  • Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Hematologia
    Santiago de Compostela, LA Coruña 15706, Spain
  • Complejo Hospitalario San Millan - San Pedro; Servicio Hematologia
    Logroño, LA Rioja 26006, Spain
  • Complejo Asistencial de León, Servicio de Hematología
    León, Leon 24008, Spain
  • Hospital Universitario de Fuenlabrada; Servicio de Hematologia
    Fuenlabrada, Madrid 28943, Spain
  • Hospital Severo Ochoa; Servicio de Hematologia
    Leganes, Madrid 28911, Spain
  • Hosital Universitario de Mostoles;Servicio de Hematologia
    Mostoles, Madrid 28935, Spain
  • Clinica Universitaria de Navarra; Servicio de Hematologia
    Pamplona, Navarra 31008, Spain
  • Hospital de Navarra, Servicio de Hematología
    Pamplona, Navarra 31008, Spain
  • Complejo Hospitalario Universitario de Vigo; Servicio de Hematologia
    Vigo, Pontevedra 36204, Spain
  • Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia
    Santa Cruz de Tenerife, Tenerife 38010, Spain
  • Hospital de Basurto; Servicio de Hematologia
    Bilbao, Vizcaya 48013, Spain
  • Hospital de Galdakano; Servicio de Hematologia
    Galdakao, Vizcaya 48960, Spain
  • Complejo Hospitalario Torrecardenas; Servicio de Hematologia
    Almeria, 04009, Spain
  • Hospital Universitario de Burgos, Servicio de Hematología
    Burgos, 09006, Spain
  • Hospital General de Castellon; Servicio de Hematologia
    Castellon, 12004, Spain
  • Hospital Universitario Reina Sofia; Servicio de Hematologia
    Cordoba, 14004, Spain
  • Hospital Universitario Virgen de las Nieves; Servicio de Hematologia
    Granada, 18014, Spain
  • Hospital Universitario de Gaudalajara; Hematología
    Guadalajara, 19002, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Hematologia
    Lerida, 25198, Spain
  • Hospital Infanta Leonor; Servicio de Hematologia
    Madrid, 28031, Spain
  • Fundacion Jimenez Diaz; Servicio de Hematologia
    Madrid, 28040, Spain
  • Hospital Universitario Clínico San Carlos; Servicio de Hematología
    Madrid, 28040, Spain
  • HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio Hematologia
    Madrid, 28050, Spain
  • Hospital Universitario Puerta de Hierro; Servicio de Hematologia
    Madrid, 28222, Spain
  • Hospital Universitario Principe de Asturias; Servicio de Hematología
    Madrid, 28805, Spain
  • Hospital Univ. Virgen de la Victoria
    Malaga, 29010, Spain
  • Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología
    Murcia, 30008, Spain
  • Hospital Universitario Virgen de Arrixaca; Servicio de Hematologia
    Murcia, 30120, Spain
  • Complejo Hospitalario de Pontevedra; Servicio de Hematologia
    Pontevedra, 36071, Spain
  • Complejo Asistencial de Segovia
    Segovia, 40002, Spain
  • Hospital Universitario Virgen Macarena; Servicio de Hematologia
    Sevilla, 41009, Spain
  • Hospital Univ. Nuestra Señora de Valme; Servicio de Hematologia
    Sevilla, 41014, Spain
  • Hospital de Rio Hortega; Servicio de Hematologia
    Valladolid, 47010, Spain
09

References and documents

Publications

  • Petrini M, Gaidano G, Mengarelli A, Consoli U, Santoro A, Liberati AM, Ladetto M, Fraticelli V, Guarini A, Mannina D, Ferrando P, Corradini P, Musto P, Stelitano C, Marino D, Camera A, Murineddu M, Battistini R, Caparrotti G, Turrini M, Arcaini L, Santini S, Cerqueti M, Ferreri AJM, Cantore N, Inzoli A, Cardinale G, Ronci B, La Nasa G, Massimi S, Gaglione G, Barbiero V, Martelli M. Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. Adv Hematol. 2022 Jan 27;2022:5581772. doi: 10.1155/2022/5581772. eCollection 2022. PubMed 35126524 ↗
  • Garcia-Munoz R, Quero C, Perez-Persona E, Domingo-Garcia A, Perez-Lopez C, Villaescusa-de-la-Rosa T, Martinez-Castro AM, Arguinano-Perez JM, Parra-Cuadrado JF, Panizo C. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. 2020 Mar;188(5):661-673. doi: 10.1111/bjh.16227. Epub 2019 Oct 1. PubMed 31573078 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Apr 2017, 41 months.

Results were first posted in Jul 2018, 1 year 2 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 41 months is below that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 19, 2013
StartActual
Nov 11, 2013
Primary completionActual
Apr 11, 2017
CompletionActual
Apr 11, 2017
Results first posted
Jul 5, 2018
Last update
Dec 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01987505
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Nov 11, 2013
Primary completion
Apr 11, 2017
Completion
Apr 11, 2017
Results posted
Jul 5, 2018
Last update
Dec 26, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion